Navigation Links
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
Date:7/22/2008

- Systemic treatment with chemotherapy and pegylated enzyme produces

significantly enhanced survival compared to chemotherapy alone -

- Pegylated enzyme well tolerated -

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA. The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous PEGPH20 in combination with the chemotherapeutic drugs, docetaxel (Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a substantial increase in anti-tumor activity. The docetaxel combination treatment demonstrated significantly enhanced survival compared to treatment with the chemotherapeutic agent alone. The effects of PEGPH20 were selective to prostate tumors producing hyaluronan (HA), consistent with the selective reduction of tumor interstitial fluid pressure (IFP). Treatment with PEGPH20 was well tolerated in non tumor-bearing mice without significant increases in neutropenia (depletion of neutrophils, a type of white blood cell) compared to chemotherapy alone.

"These findings clearly demonstrate the activity of our long acting PEGPH20 enzyme candidate against HA-rich tumors in combination with chemotherapy," said Gregory Frost, PhD, Halozyme's Vice President and Chief Scientific Officer. "By targeting tumors that overproduce the HA matrix component, PEGPH20 may selectively att
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
2. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
3. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
6. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
7. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
8. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
9. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
10. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
11. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  ADM Tronics Unlimited, Inc. (OTCQB: ... to its corporate Advisory Board for business development. ... the Harvard Medical School and Visiting Professor at ... his Masters degree in Electronics Engineering and his ... of Bologna. After spending a year as a ...
(Date:9/18/2014)... 18, 2014  ePharmaSolutions, the leading provider ... the Disruptive Innovator of the Year at ... platform. This solution includes an integrated clinical ... (eTMF), a remote monitoring application, eSource and ... screening and matching technology. The ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... United Arab Emirates, Sept. 22 NewBridge Pharmaceuticals announced ... agreement with Orexo AB (STO: ORX) that grants NewBridge ... treatment of breakthrough cancer pain, in the Middle East ... and sell the product in these territories.  The agreement ...
... Decision Resources, one of the world,s leading research and ... to generic erosion of key agents, the colorectal cancer drug ... from more than $6.4 billion in 2009 to just under ... Italy, Spain, United Kingdom and Japan. The Pharmacor ...
Cached Medicine Technology:NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 2NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 3NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 4Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019 2Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019 3
(Date:9/18/2014)... September 18, 2014 According to a new ... Services Market - Global Industry Analysis, Size, Share, Growth, Trends ... services market was valued at USD 77607.7 million in 2013 ... from 2014 to 2020, to reach an estimated value of ... and services market is growing at a rapid pace due ...
(Date:9/18/2014)... September 18, 2014 The new ... boon to contractors and homeowners alike as it ... overtakes the home, causes potential health issues, and ... nationwide, the BuildClean system allows contractors to virtually ... and other standard remodeling tasks. , BuildClean removes ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical ... — EV™ for physicians — improving ... best-of-breed solutions, Holyoke chose T-System’s solution because not ... and reimbursement, but also its ability to integrate ... used to capture emergency department, (ED) nurse documentation. ...
(Date:9/18/2014)... the popular online supplier of funny figurines, has added a ... line. Moreover, all the company’s products are now offered with ... special offer before September 29, 2014. Customers who place bulk ... bobblehead doll ). , “We are pleased to ... make our interesting items available to all the global customers. ...
(Date:9/18/2014)... How much is a serving? , Most ... to the obesity epidemic in the United States. ... to manage portion size during the next “Healthy Eating ... House, 755 Ohltown Road, Austintown. , Registered dietician and ... and answer questions from 12:30 to 2 p.m. Oct. ...
Breaking Medicine News(10 mins):Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:Discounted Custom Bobbleheads Online For Sale At WowBobble.com 2Health News:HMHP Workshop Addresses Portion Control 2
... N.Y. study finds that weather warmer than 75 degrees poses ... research suggests that cocaine overdose deaths in New York City ... average weekly temperature goes past 75 degrees Fahrenheit. , ... Addiction , are based on death statistics in the city ...
... Researchers say defibrillators can be turned off on admission, ... care for people who are dying often forget to ... research has found. , Only 20 percent of more ... that they had a question on their admitting form ...
... , ... ... ... ...
... ... ... , ... , , , ...
... new study, led by researchers at the Herbert Irving ... demonstrates that acupuncture may be an effective therapy for ... are being treated with commonly used hormonal therapies. Results ... . Joint pain and stiffness are common side ...
... it possible to build supercomputers that can replicate the ... to an implantable chip for interfacing with neurons and ... nanoscience and neuroscience are now advancing each other in ... what this means was the topic of an hour-long ...
Cached Medicine News:Health News:Hearts of Hospice Patients Being Needlessly Shocked 2Health News:Hearts of Hospice Patients Being Needlessly Shocked 3Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 2Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 4Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 5Health News:Acupuncture may relieve joint pain caused by some breast cancer treatments 2
Inquire...
Inquire...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
Medicine Products: